Silvan Tuerkcan
Stock Analyst at JMP Securities
(2.11)
# 2,574
Out of 4,670 analysts
132
Total ratings
36.72%
Success rate
-4.86%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Initiates: Market Outperform | $18 | $7.68 | +134.38% | 1 | Nov 18, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Market Outperform | $5 | $2.47 | +102.43% | 11 | Nov 12, 2024 | |
| MGNX MacroGenics | Downgrades: Market Perform | n/a | $3.24 | - | 12 | Nov 7, 2024 | |
| EXEL Exelixis | Maintains: Market Outperform | $29 → $34 | $35.61 | -4.52% | 17 | Oct 16, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Market Outperform | $70 | $22.05 | +217.46% | 3 | Oct 15, 2024 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $16 → $18 | $10.49 | +71.59% | 9 | Oct 14, 2024 | |
| RLAY Relay Therapeutics | Reiterates: Market Outperform | $21 | $4.75 | +342.11% | 9 | Sep 17, 2024 | |
| ACRV Acrivon Therapeutics | Reiterates: Market Outperform | $17 | $6.55 | +159.54% | 4 | Sep 16, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $15 → $20 | $5.79 | +245.42% | 10 | Sep 10, 2024 | |
| VOR Vor Biopharma | Reiterates: Market Outperform | $12 | $0.79 | +1,418.99% | 10 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $7 | $0.60 | +1,060.09% | 4 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.87 | +220.86% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $86 | $47.88 | +79.62% | 12 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $284.59 | -1.61% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.37 | - | 7 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.74 | +53.32% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $14.30 | - | 10 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $2 → $3 | $7.10 | -57.75% | 3 | May 10, 2022 |
enGene Holdings
Nov 18, 2024
Initiates: Market Outperform
Price Target: $18
Current: $7.68
Upside: +134.38%
Taysha Gene Therapies
Nov 12, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $2.47
Upside: +102.43%
MacroGenics
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.24
Upside: -
Exelixis
Oct 16, 2024
Maintains: Market Outperform
Price Target: $29 → $34
Current: $35.61
Upside: -4.52%
Jasper Therapeutics
Oct 15, 2024
Reiterates: Market Outperform
Price Target: $70
Current: $22.05
Upside: +217.46%
Benitec Biopharma
Oct 14, 2024
Maintains: Market Outperform
Price Target: $16 → $18
Current: $10.49
Upside: +71.59%
Relay Therapeutics
Sep 17, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $4.75
Upside: +342.11%
Acrivon Therapeutics
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $6.55
Upside: +159.54%
Terns Pharmaceuticals
Sep 10, 2024
Maintains: Market Outperform
Price Target: $15 → $20
Current: $5.79
Upside: +245.42%
Vor Biopharma
Sep 6, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $0.79
Upside: +1,418.99%
Jul 15, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $0.60
Upside: +1,060.09%
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.87
Upside: +220.86%
May 9, 2024
Reiterates: Market Outperform
Price Target: $86
Current: $47.88
Upside: +79.62%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $284.59
Upside: -1.61%
Oct 23, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.37
Upside: -
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.74
Upside: +53.32%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $14.30
Upside: -
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $7.10
Upside: -57.75%